Status:

COMPLETED

Topiramate in Adolescents With Severe Obesity

Lead Sponsor:

University of Minnesota

Conditions:

Obesity, Morbid

Obesity

Eligibility:

All Genders

12-17 years

Phase:

PHASE2

Brief Summary

The prevalence of severe pediatric obesity is on the rise and youth with this condition are at elevated risk for developing chronic diseases such as cardiovascular disease (CVD) and type 2 diabetes me...

Detailed Description

The prevalence of severe pediatric obesity is on the rise and youth with this condition are at elevated risk for developing chronic diseases such as cardiovascular disease (CVD) and type 2 diabetes me...

Eligibility Criteria

Inclusion

  • BMI ≥1.2 times the 95th percentile (based on gender and age) or BMI ≥35 kg/m2
  • 12-18 years old
  • Tanner stage IV or V by physical exam

Exclusion

  • Tanner stage I, II, or III
  • Type 1 or 2 diabetes mellitus
  • Previous (within 6-months) or current use of weight loss medication (patients may undergo washout)
  • Previous (within 6-months) or current use of drugs associated with weight gain (e.g. steroids/anti-psychotics)
  • Previous bariatric surgery
  • Recent initiation (within 3-months) of anti-hypertensive or lipid medication
  • Previous (within 6-months) or current use of medication to treat insulin resistance or hyperglycemia (patients may undergo washout)
  • Major psychiatric disorder
  • Females: Pregnant, planning to become pregnant, or unwilling to use 2 or more acceptable methods of contraception when engaging in sexual activity throughout the study
  • Tobacco use
  • Liver/renal dysfunction
  • ALT or AST \>2.5 times the upper limit of normal
  • Bicarbonate \<18 mmol/L
  • Creatinine \>1.2 mg/dL
  • Glaucoma
  • Obesity associated with genetic disorder (monogenetic obesity)
  • Hyperthyroidism or uncontrolled hypothyroidism
  • History of suicidal thought/attempts
  • History of kidney stones
  • History of cholelithiasis
  • Current use of other carbonic anhydrase inhibitor

Key Trial Info

Start Date :

June 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2017

Estimated Enrollment :

34 Patients enrolled

Trial Details

Trial ID

NCT01859013

Start Date

June 1 2013

End Date

April 1 2017

Last Update

July 2 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Minnesota

Minneapolis, Minnesota, United States, 55455